ARCHIVES
VOL. 10, ISSUE 5 (2024)
A review on clinical management strategy and treatment modalities of resistant staphylococcal infections - Current scenario and future perspectives
Authors
Priyanka Tanwar, Mamta Naagar, Manish Kumar Maity
Abstract
Of all the staphylococcal species, Staphylococcus aureus is the
most often occurring cause of infections of the skin and soft tissues as well
as serious staphylococcal infections, such as Staphylococcus aureus
bacteremia (SAB). While many medications are effective against staphylococci,
antimicrobial treatment has been beset by antibiotic resistance during the past
40 years, especially resistance to beta-lactam antibiotics. The capacity of
staphylococci, particularly methicillin-resistant Staphylococcus aureus
(MRSA), to withstand the effects of beta-lactam antibiotics is now referred to
by the name "methicillin resistance," which has historical
significance. The mecA gene, which is included in the SCC mec
complex genetic cassette, encodes this resistance. Older antibiotics and
vancomycin continue to be the mainstays of treatment for staphylococci that are
resistant. The medicines that are the subject of this review,
trimethoprim-sulfamethoxazole, ceftaroline, daptomycin, fosfomycin, linezolid,
dalbavancin, televancin, and omadacycline, exhibit good action against
resistant staphylococci. Novel modes of action for individual
anti-staphylococcal drugs or in combination to enhance the activity of the
primary anti-staphylococcal agent are being developed. Despite several
drawbacks, including the potential for renal impairment, vancomycin therapy is
still the gold standard for treating resistant staphylococcal infections. When
renal impairment first appears, several medical professionals move from
vancomycin as soon as possible. The near future may potentially bring about an
improvement in the humoral and cellular defences against staphylococcal
infection. The selection of antibiotics and the length of anti-staphylococcal
therapy will depend on professional clinical judgement until more recent
clinical trials demonstrate the unmistakable advantage of one anti-staphylococcal
medication over another or over vancomycin.
Download
Pages:26-30
How to cite this article:
Priyanka Tanwar, Mamta Naagar, Manish Kumar Maity "A review on clinical management strategy and treatment modalities of resistant staphylococcal infections - Current scenario and future perspectives". International Journal of Medical and Health Research, Vol 10, Issue 5, 2024, Pages 26-30
Download Author Certificate
Please enter the email address corresponding to this article submission to download your certificate.